Author

Maurice Perrinjaquet

Observed names: M Perrinjaquet, M. Perrinjaquet

Observed institution: Navigant (Germany)

OpenAlex ID: A5020809050

Personalized neoantigen cancer vaccines: An analysis of the clinical and commercial potential of ongoing development programs

2023 · Maurice Perrinjaquet, C. Richard Schlegel · Drug Discovery Today · 12

Adjuvant Therapy Versus Watch-and-Wait Post Surgery for Stage III Melanoma: A Multicountry Retrospective Chart Review

2019 · Peter Mohr, Felix Kiecker, et al. · Melanoma Management · 12

Burden of illness in hereditary periodic fevers: a multinational observational patient diary study.

2020 · Jasmin B Kuemmerle-Deschner, Pierre Quartier, et al. · PubMed · 11

Pcn305 Funding Trends for In-hospital Drugs: German Nub Analysis

2019 · B. Sanchez Vazquez, Z.R. Miller, et al. · Value in Health

P1.16-46 Genetic Testing Patterns, Treatment Characteristics, and Overall Survival in ALK-Positive Metastatic NSCLC Patients Treated with Ceritinib

2019 · J. Mazieres, M. Ahn, et al. · Journal of Thoracic Oncology

Treatment patterns and overall survival in patients with BRAF-mutated metastatic non-small cell lung cancer

2018 · R.K. Goyal, A. Kron, et al. · Annals of Oncology

Comparison of the Assessments and Recommendations Issued by Brazil’s Conitec and Canada’s Cadth for Select Oncology Drugs

2017 · J Montilva, M Perrinjaquet, et al. · Value in Health

Works count: 7

Citation count: 35

H-index: 3

I10-index: 3